#United States #New York #Levi & Korsinsky #Actinium Pharmaceuticals #NYSE:ATNM

Important Reminder for Actinium Investors

Levi & Korsinsky, LLP, a prominent law firm dedicated to protecting shareholders, has recently alerted investors about an impending opportunity to participate in a class action lawsuit involving Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This lawsuit addresses serious allegations of securities fraud affecting investors who suffered losses between October 31, 2022, and August 2, 2024. Shareholders must take note of the critical deadline set for May 27, 2025, for appointing a lead plaintiff.

Background of the Case

This class action aims to hold Actinium accountable for allegedly misleading statements and concealed information regarding the company's Phase 3 Sierra trial. According to the complaint, the defendants misrepresented crucial data and downplayed the challenges related to the acceptance and approval of the Iomab-B biologics license application (BLA) by the FDA. The lawsuit highlights potential implications which raised concerns about the robustness of the trial results and the likelihood of regulatory approval.

Allegations Detailing Securities Fraud

The key allegations include that:
1. The data from the Sierra trial was unlikely to comply with FDA guidelines, thus jeopardizing the chances for Iomab-B's acceptance.
2. Additional analyses provided to the FDA may not have effectively mitigated the trial's unfavorable outcomes, leading to further uncertainty about the approval process.
3. The defendants’ overly optimistic assertions about the company’s operational success were misleading and lacked a sufficient factual base.

These claims reflect a lack of transparency that could have influenced shareholder decisions, leading to significant financial losses.

Investors' Next Steps

Investors who believe they have suffered financial harm hold the opportunity to request the court to designate them as a lead plaintiff by the deadline. Importantly, participating in this action does not necessitate that investors act as lead plaintiffs to be eligible for any potential recovery of losses incurred during the specified timeframe.

Eligibility and No-cost Participation

Levi & Korsinsky emphasizes that affected Actinium shareholders could participate in the lawsuit without incurring out-of-pocket costs or obligations. The firm has built a strong reputation over the past two decades for successfully representing shareholders in complicated securities litigation, recovering substantial amounts for its clients. Investors are encouraged to become part of this effort to seek accountability and potential restitution.

A Leader in Securities Litigation

With a team of over 70 dedicated professionals, Levi & Korsinsky ranks among the top securities litigation firms in the United States. For seven consecutive years, the firm has been recognized in ISS Securities Class Action Services' Top 50 Report, showcasing its expertise and success in handling high-stakes cases. Notably, they have secured hundreds of millions of dollars in settlements for shareholders in the past, affirming their commitment to investor interests.

Contact Information

For additional details regarding participation in the Actinium class action lawsuit, investors are encouraged to reach out to Joseph E. Levi, Esq., via the following contact methods:

• - Email: info@zlk.com
• - Phone: (212) 363-7500

Conclusion

This reminder serves not only as a call to action for those who have invested in Actinium Pharmaceuticals but also highlights the critical importance of shareholder vigilance in protecting their rights. The upcoming deadline necessitates swift action by affected parties to ensure their interests are represented, setting the stage for a potential collective recovery in the face of alleged securities fraud.